Outset Medical, Inc. Stock Price, News & Analysis

Outset Medical, Inc. (NASDAQ: OM) announced its expected fourth quarter and fiscal year 2022 revenues, projecting approximately $31.5 million for Q4, a 13% increase from Q3, and $115 million for the year, up 12% year-over-year. The installed base of its Tablo® Hemodialysis Systems surged 54% to around 4,000 units. For 2023, Outset anticipates revenues of $140 million to $150 million and a gross margin increase to 20%. The company emphasizes its growth in treating patients and expanding its market presence.

Outset Medical, Inc. (Nasdaq: OM) announces its participation in the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023, at 11:15 am PT / 2:15 pm ET. The company focuses on innovative dialysis technology, specifically the Tablo Hemodialysis System, designed to reduce costs and complexity in dialysis treatments. The Tablo system, FDA cleared for both hospital and home use, allows healthcare providers to deliver dialysis care more efficiently. A live and archived webcast will be available on Outset's Investors webpage.

Outset Medical, Inc. (Nasdaq: OM) announces participation in a virtual panel at the BofA Securities Home Care Conference on December 6, 2022, at 12:10 PM PT. The discussion will feature CEO Leslie Trigg and CMO Michael Aragon, alongside two home dialysis patients, focusing on home hemodialysis and end-stage renal disease management. A live and archived webcast will be accessible on the Investors section of Outset’s website. Outset's Tablo® Hemodialysis System aims to simplify dialysis and enhance patient care.

Outset Medical, Inc. announced a remarkable 5,000% revenue growth, totaling $103 million from 2018 to 2021, largely attributed to the adoption of its Tablo® Hemodialysis System. The company ranked 33 on the Deloitte Technology Fast 500 list, reflecting its leadership in the medical technology sector. Outset’s technology aims to simplify dialysis for patients and providers, offering a seamless experience from hospitals to home care.

Outset Medical, Inc. (Nasdaq: OM) announced management participation in two investor conferences. The Stifel 2022 Healthcare Conference is set for November 15, 2022, at 5:35am PT. The Jefferies London Healthcare Conference follows on November 17, 2022, at 5:55am PT. Both sessions will be accessible via live and archived webcasts on the Outset website. Outset is known for its innovative Tablo Hemodialysis System, which simplifies dialysis cost and complexity, enhancing patient care from hospitals to home.

Outset Medical reported a 10.8% revenue growth in Q3 2022, reaching $27.8 million, compared to $25.1 million in Q2 2022. Gross margin improved to 15.6% from 11.2% in Q3 2021. Full-year revenue guidance is now set between $111 million and $113 million, up from previous guidance of $105 million to $110 million. Key achievements include resuming shipments to home patients and a five-year contract with the Department of Veterans Affairs.

Outset Medical, Inc. (Nasdaq: OM) has secured $300 million in senior secured credit facilities from SLR Capital Partners, including a $250 million term loan and a $50 million revolving credit facility. The term loan includes a $200 million commitment, extendable to $250 million, with interest-only payments for up to 54 months. Outset has drawn $100 million at closing. The financing aims to enhance the company's balance sheet and support its dialysis technology advancements. Maturity is set for November 1, 2027.

Outset Medical announces eight new abstracts highlighting home dialysis innovations at the American Society of Nephrology's Kidney Week 2022. Research indicates that patients using the Tablo Hemodialysis System experience lower attrition rates compared to other modalities, demonstrating high treatment adherence with 100% patient retention. Key findings emphasize that both patients and clinicians can effectively use the technology. Abstracts also showcase improved efficiency, cost reduction, and successful home dialysis program implementation, reflecting Outset's commitment to enhancing kidney care.

Outset Medical, Inc. (OM) will release its third-quarter financial results on November 8, 2022, after market close. A conference call is scheduled for 2:00 PM PT on the same day, featuring CEO Leslie Trigg and CFO Nabeel Ahmed. Interested parties can register online to receive dial-in information. Outset is known for its innovative Tablo® Hemodialysis System, designed to make dialysis more accessible and efficient, supporting care from hospital to home. This technology integrates water purification and dialysate production, enhancing patient experience and operational efficiency.